Abe S, Takahashi K, Yamazaki M, Mizuno D
Jpn J Cancer Res. 1985 Jul;76(7):626-30.
Several types of combination therapy, including OK432, cyclophosphamide (CY), and/or lentinan plus bacterial lipopolysaccharide (LPS), reported to have strong antitumor activity against some tumors, were only slightly effective on Lewis lung carcinoma (LC) in C57BL/6 mice. Combination therapy by intralesional injection of OK432 followed by intraperitoneal administration of CY, lentinan and LPS caused almost complete regression of intradermal solid-type LC. Maximal antitumor activity was observed when lentinan and LPS were administered later than CY. Mice in which LC had regressed due to this combination therapy showed an antitumor delayed hypersensitivity reaction (measured by the footpad test), but they were not resistant to rechallenge with LC. These results provide a new model for combination therapy against weakly immunogenic tumors.
据报道，几种联合疗法，包括OK432、环磷酰胺（CY）和/或香菇多糖加细菌脂多糖（LPS），对某些肿瘤具有很强的抗肿瘤活性，但对C57BL/6小鼠的Lewis肺癌（LC）仅有轻微疗效。通过瘤内注射OK432，随后腹腔注射CY、香菇多糖和LPS进行联合治疗，可使皮内实体型LC几乎完全消退。当香菇多糖和LPS比CY更晚给药时，观察到最大抗肿瘤活性。因这种联合疗法导致LC消退的小鼠表现出抗肿瘤迟发型超敏反应（通过足垫试验测量），但它们对再次接种LC没有抵抗力。这些结果为针对弱免疫原性肿瘤的联合治疗提供了一个新模型。
